Harrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars

Reuters

2025/07/17

Harrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars

Harrow Inc., a prominent North American eyecare pharmaceutical company, has announced a strategic expansion through a definitive agreement with Samsung Bioepis Co. Ltd. This agreement grants Harrow exclusive U.S. commercial rights to Samsung Bioepis' ophthalmology biosimilar portfolio, including BYOOVIZ® and OPUVIZ™, both FDA-approved biosimilars referencing well-established anti-VEGF therapies Lucentis and Eylea, respectively. Harrow aims to leverage its established commercial infrastructure to enhance market accessibility and affordability of these treatments for retinal diseases, a market valued at $9 billion in the U.S. By 2025, Harrow will assume full commercial responsibility for these products, potentially reducing the financial burden on Medicare and commercial plans while expanding patient access.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harrow Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250717236374) on July 17, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2552485955"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2552485955\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2552485955?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-17 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552485955","market":"fut","top_or_hot":-1,"title":"Harrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Harrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Harrow Inc., a prominent <a href=\"https://laohu8.com/S/FNCSF\">North American</a> eyecare pharmaceutical company, has announced a strategic expansion through a definitive agreement with Samsung Bioepis Co. Ltd. This agreement grants Harrow exclusive U.S. commercial rights to Samsung Bioepis' ophthalmology biosimilar portfolio, including BYOOVIZ® and OPUVIZ™, both FDA-approved biosimilars referencing well-established anti-VEGF therapies Lucentis and Eylea, respectively. Harrow aims to leverage its established commercial infrastructure to enhance market accessibility and affordability of these treatments for retinal diseases, a market valued at $9 billion in the U.S. By 2025, Harrow will assume full commercial responsibility for these products, potentially reducing the financial burden on Medicare and commercial plans while expanding patient access.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harrow Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250717236374) on July 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-17 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Harrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Harrow Inc., a prominent <a href=\"https://laohu8.com/S/FNCSF\">North American</a> eyecare pharmaceutical company, has announced a strategic expansion through a definitive agreement with Samsung Bioepis Co. Ltd. This agreement grants Harrow exclusive U.S. commercial rights to Samsung Bioepis' ophthalmology biosimilar portfolio, including BYOOVIZ® and OPUVIZ™, both FDA-approved biosimilars referencing well-established anti-VEGF therapies Lucentis and Eylea, respectively. Harrow aims to leverage its established commercial infrastructure to enhance market accessibility and affordability of these treatments for retinal diseases, a market valued at $9 billion in the U.S. By 2025, Harrow will assume full commercial responsibility for these products, potentially reducing the financial burden on Medicare and commercial plans while expanding patient access.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harrow Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250717236374) on July 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250717:nNDL9dtc3g:1","article_id":"2552485955","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552485955","pubTimestamp":1752750045,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Harrow Inc., a prominent North American eyecare pharmaceutical company, has announced a strategic expansion through a definitive agreement with Samsung Bioepis Co. Ltd. This agreement grants Harrow exclusive U.S. commercial rights to Samsung Bioepis' ophthalmology biosimilar portfolio, including BYOOVIZ and OPUVIZ, both FDA-approved biosimilars referencing well-established anti-VEGF therapies Lucentis and Eylea, respectively. Harrow aims to leverage its established commercial infrastructure to enhance market accessibility and affordability of these treatments for retinal diseases, a market valued at $9 billion in the U.S. By 2025, Harrow will assume full commercial responsibility for these products, potentially reducing the financial burden on Medicare and commercial plans while expanding patient access.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generate","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4557":"大麻股","HROW":"Harrow Health Inc"},"translate_title":"Harrow Inc.拥有三星Bioepis眼科生物仿制药的独家权利，扩大在美国的业务","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HROW":0.9},"content_text":"Harrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars\n    \n\n        Harrow Inc., a prominent North American eyecare pharmaceutical company, has announced a strategic expansion through a definitive agreement with Samsung Bioepis Co. Ltd. This agreement grants Harrow exclusive U.S. commercial rights to Samsung Bioepis' ophthalmology biosimilar portfolio, including BYOOVIZ® and OPUVIZ™, both FDA-approved biosimilars referencing well-established anti-VEGF therapies Lucentis and Eylea, respectively. Harrow aims to leverage its established commercial infrastructure to enhance market accessibility and affordability of these treatments for retinal diseases, a market valued at $9 billion in the U.S. By 2025, Harrow will assume full commercial responsibility for these products, potentially reducing the financial burden on Medicare and commercial plans while expanding patient access.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harrow Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250717236374) on July 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}